Source:http://linkedlifedata.com/resource/pubmed/id/18338983
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2008-10-24
|
pubmed:abstractText |
Human U-II (urotensin-II), the most potent vasoconstrictor peptide identified to date, is associated with cardiovascular disease. A single nucleotide polymorphism (S89N) in the gene encoding U-II (UTS2) is associated with the onset of Type 2 diabetes and insulin resistance in the Japanese population. In the present study, we have demonstrated a relationship between plasma U-II levels and the progression of diabetic retinopathy and vascular complications in patients with Type 2 diabetes. Eye fundus, IMT (intima-media thickness) and plaque score in the carotid artery, BP (blood pressure), FPG (fasting plasma glucose), HbA(1c) (glycated haemoglobin), U-II, angiogenesis-stimulating factors, such as VEGF (vascular endothelial growth factor) and heregulin-beta(1), and lipid profiles were determined in 64 patients with Type 2 diabetes and 24 non-diabetic controls. FPG, HbA(1c) and VEGF levels were significantly higher in patients with Type 2 diabetes than in non-diabetic controls. Diabetes duration, insufficient glycaemic and BP control, plasma U-II levels, IMT, plaque score and nephropathy grade increased significantly across the subjects as follows: non-diabetic controls, patients with Type 2 diabetes without retinopathy (group N), patients with Type 2 diabetes with simple (background) retinopathy (group A) and patients with Type 2 diabetes with pre-proliferative and proliferative retinopathy (group B). The prevalence of obesity and smoking, age, low-density lipoprotein, triacylglycerols (triglycerides) and heregulin-beta(1) were not significantly different among the four groups. In all subjects, U-II levels were significantly positively correlated with IMT, FPG, and systolic and diastolic BP. Multiple logistic regression analysis revealed that, of the above parameters, U-II levels alone had a significantly independent association with diabetic retinopathy. In conclusion, the results of the present study provide the first evidence that increased plasma U-II levels may be associated with the progression of diabetic retinopathy and carotid atherosclerosis in patients with Type 2 diabetes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Urotensins,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/urotensin II
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1470-8736
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
115
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
327-34
|
pubmed:meshHeading |
pubmed-meshheading:18338983-Aged,
pubmed-meshheading:18338983-Biological Markers,
pubmed-meshheading:18338983-Blood Glucose,
pubmed-meshheading:18338983-Blood Pressure,
pubmed-meshheading:18338983-Carotid Artery Diseases,
pubmed-meshheading:18338983-Diabetes Mellitus, Type 2,
pubmed-meshheading:18338983-Diabetic Angiopathies,
pubmed-meshheading:18338983-Diabetic Retinopathy,
pubmed-meshheading:18338983-Epidemiologic Methods,
pubmed-meshheading:18338983-Female,
pubmed-meshheading:18338983-Humans,
pubmed-meshheading:18338983-Male,
pubmed-meshheading:18338983-Middle Aged,
pubmed-meshheading:18338983-Severity of Illness Index,
pubmed-meshheading:18338983-Urotensins,
pubmed-meshheading:18338983-Vascular Endothelial Growth Factor A
|
pubmed:year |
2008
|
pubmed:articleTitle |
Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.
|
pubmed:affiliation |
First Department of Internal Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|